Alamar Biosciences Highlights NULISA Data in 46 Presentations at CTAD 2026, Including 10 Oral Presentations
Alamar Biosciences, Inc. (ALMR) Presents at 2026 UBS Global Healthcare Conference Transcript
Alamar Biosciences: Recurring Revenue Potential At A High Premium
Does Alamar Biosciences (ALMR) Sit Above Fair Value After The Selloff?
Alamar Biosciences to Participate in Upcoming Investor Conferences
Alamar Biosciences (ALMR) Q3 2026 Earnings Call Transcript
TD Cowen Maintains Buy on Alamar Biosciences, Raises Price Target to $36
Alamar Biosciences (ALMR) Could Be 15% Undervalued On Q3 Results And Guidance
Alamar Biosciences Inc (ALMR) (Q3 2026) Earnings Call Highlights: Revenue Jumps 68% as Guidance ...
Alamar Biosciences Q3 Earnings Call Highlights
Alamar (ALMR) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Alamar Biosciences, Inc. (ALMR) Q3 2026 Earnings Call Transcript
Alamar: Q3 Earnings Snapshot
Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
Alamar Biosciences Q3 2026 Earnings Call Transcript
Alamar Biosciences Raises FY2026 Sales Guidance from $116.000M-$120.000M to $121.000M-$123.000M vs $118.632M Est
Alamar Biosciences Q3 EPS $(0.19); Sales $33.55M Up 68% From $19.91M YoY
Alamar Biosciences Partners With GSK For Its Use Of NULISA Platform In Trial To Evaluate Protein Signatures Regarding Disease Progression, Biological Subtypes And Treatment Response Across Respiratory, Liver, Kidney, Neurological And Autoimmune Conditions
Emory Researchers Identify Blood Protein Signature That Detects ALS With 98% Accuracy Using Alamar Technology
Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.